Outcome MeasureWell-being

PANAS

Positive and Negative Affect Schedule

2 Papers in Blossom

Clinical Thresholds

1050
Low affect
Score 10–25
Moderate affect
Score 26–38
High affect
Score 39–50

Outcome Data Across Studies

Reported results for PANAS across 1 study with quantitative data.

Outcome data across 2 study arm–timepoint observations
SD
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
2023Exploratory
25 mg COMP360(experimental)01919.37.2—
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication
2023Exploratory
25 mg COMP360(experimental)21927.4——

Papers Using PANAS

Paywallindividual

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis

In a retrospective analysis of 233 participants with treatment‑resistant depression given 1, 10 or 25 mg COMP360 psilocybin, dose was the strongest and most consistent predictor of the acute psychedelic experience, while pretreatment clinical characteristics made only modest, variable contributions (positive affect, lower generalized anxiety, higher executive function and greater personality‑disorder symptoms each influenced different experience dimensions). These results challenge the assumption that pretreatment traits are major determinants of the subjective psilocybin experience.

Published
Journal
Journal of Clinical Psychopharmacology
Authors
Kirlić, N., Atli, M., Mistry, S., Gold, M., Goodwin, G. M.
Open Accessindividual

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

This open-label Phase II trial (n=19) investigates the safety, tolerability, and efficacy of synthetic psilocybin (COMP360) as an adjunct to selective serotonin reuptake inhibitors (SSRIs) in adults with treatment-resistant depression (TRD). The study found no serious treatment-emergent adverse events or increased suicidal ideation. It reported a significant decrease in depression (MADRS) and Clinical Global Impression-Severity (CGI-S) scores at week 3, with response and remission observed in 42.1% of participants.

Published
Journal
Neuropharmacology
Authors
Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., O'keane, V., Peck, S. K., Simmons, H., Sisa, C., Stansfield, S. C., Tsai, J., Williams, S., Malievskaia, E.

Quick Facts

Full Name
Positive and Negative Affect Schedule
Domain
Well-being
Papers Indexed
2
Score Range
10–50
Interpretation
Higher = better
Unit
points
All Measures